Ipsen appoints Michelle Werner as North America head Ipsen has appointed biopharma industry veteran Michelle Werner, who recently stepped down as CEO of Alltrna, to lead its North America division.

#Ipsen has appointed #biopharma industry veteran #MichelleWerner to lead its #NorthAmerica business, as it pushes an ambitious #growthstrategy powered by intense dealmaking across oncology, rare diseases, and neuroscience.

pharmaphorum.com/news/ipsen-a...

Safety concerns prompt Ipsen to pull Tazverik from market Ipsen is voluntarily withdrawing its EZH2 inhibitor Tazverik from sale after a clinical trial suggested a link with secondary blood cancers.

#Ipsen is voluntarily withdrawing its EZH2 inhibitor #Tazverik from sale after a clinical trial suggested a link with #secondarybloodcancers.

Quotient Sciences Enhances Manufacturing Partnership for Ultra-Rare Disease Treatment Quotient Sciences has announced an extended partnership with Ipsen to manufacture a groundbreaking therapy for the ultra-rare disease Fibrodysplasia Ossificans Progressiva (FOP).

Quotient Sciences Enhances Manufacturing Partnership for Ultra-Rare Disease Treatment #United_States #Philadelphia #Ipsen #Quotient_Sciences #Fibrodysplasia

Seigo Noda Appointed as CEO of Ipsen Japan to Enhance Business Growth Seigo Noda has officially assumed the role of CEO of Ipsen Japan as of January 1, 2026, aiming to strengthen operations and patient care.

Seigo Noda Appointed as CEO of Ipsen Japan to Enhance Business Growth #Japan #Tokyo #Ipsen #Seigo_Noda

IPSEN新社長に野田征吾氏が就任し未来の医療に挑む IPSEN株式会社は、2026年1月1日付で野田征吾氏が代表取締役社長に就任したと発表。医療ニーズに応じた戦略を強化し、患者のための革新に力を入れる。

IPSEN新社長に野田征吾氏が就任し未来の医療に挑む #医薬品 #IPSEN #野田征吾

IPSEN株式会社は、2026年1月1日付で野田征吾氏が代表取締役社長に就任したと発表。医療ニーズに応じた戦略を強化し、患者のための革新に力を入れる。

Malattie rare, Marchesi (Ipsen): "Sfida è portare innovazione a pazienti con Sindrome di Alagille" (Adnkronos) - “Ipsen concentra il proprio impegno nelle malattie rare, ma anche in oncologia e neuroscienze, con un obiettivo comune: offrire ai pazienti soluzioni terapeutiche innovative in aree ad alta complessità e con bisogni cli...

Malattie rare, Marchesi (Ipsen): "Sfida è portare innovazione a pazienti con Sindrome di Alagille" ... LEGGI TUTTO #MalattieRare #Innovazione #SindromeDiAlagille #Ipsen #Oncologia

Ipsen announces new data on Dysport in neurological disease - PharmaTimes Dysport reduces muscle contractions by blocking the transmission of nerve impulses

#neurology #Ipsen #Dysport #abobotulinumtoxinA #neurologicaldisease #clinicaldata #stroke #neurologicaldisorders #EPITOMEstudy #poststrokespasticity #PSS #strokepatients #realworlddata #strokesurvivors #botulinumtoxintypeA #BoNTA #PSStreatment #BoNTAinjectable #biopharmaceuticals
zurl.co/nLqKq

Who’s Out? ❌

#Merck, #Ipsen, #Sanofi and #GSK fall short overall.

Not good enough companies to be compelling for the next stage.

If you think any deserved a place, let me know!

(4/5)

Company Snapshots 🔍

2024 PEG snapshot:
📈 #NovoNordisk – growth outpacing valuation → undervalued standout.
⚖️ #Novartis, #Merck, #AstraZeneca – growth, but P/Es are sky-high.
🚫 #Sanofi, #GSK, #Ipsen – negative earnings growth = no PEG.

PEG=P/E÷growth → simple in theory, tricky in practice!

(2/5)

2020–2024 results:

The picture splits sharply:
🟢 #Novartis: strong margin gains, signaling real efficiency wins.
🟡 #NovoNordisk: rare balance of high growth and stable margins.
🔴 #Sanofi, #GSK, #Ipsen: margin erosion despite growth.
⚪ #AstraZeneca & #Merck: steady on both fronts.

(2/5)

⚡️ #ImCheck racheté par #Ipsen : une transaction historique pour la #Biotech française

Si cette opération à 1 milliard d'€ est validée par les autorités réglementaires, il s'agirait de l'une des + grosses ventes franco-françaises de l'histoire de la #FrenchTech
www.lesechos.fr/start-up/dea...

#Ipsen has agreed to buy ImCheck and its anti-BTN3A antibody for acute myeloid leukaemia in a deal that could be worth up to €1bn.

pharmaphorum.com/news/ipsen-b...

EQT Life Sciences' ImCheck Therapeutics Acquired by Ipsen for Up to €1 Billion EQT Life Sciences' ImCheck Therapeutics is being acquired by Ipsen in a significant deal worth up to €1 billion, marking a major milestone for innovation in immuno-oncology.

EQT Life Sciences' ImCheck Therapeutics Acquired by Ipsen for Up to €1 Billion #France #EQT_Life_Sciences #Marseille #Ipsen #ImCheck_Therapeutics

👶🆘 IPSEN = Initiation aux Premiers Secours Enfant et Nourrisson

9 stagiairesformés ce 10/07 à la @CroixRouge76 ✅
Félicitations à eux 👏

📅 Prochaine session : 1er août
🔗 Inscriptions : inscription-formation.croix-rouge.fr/inscription-1

#IPSEN #CroixRouge #PremiersSecours

Major Milestone: Phase 1 Trials Begin for New Cancer Treatment by IRIC and Ipsen The Université de Montréal's IRIC announces the start of a Phase 1 trial for a new small molecule therapy aimed at combatting solid tumors, partnered with Ipsen.

Major Milestone: Phase 1 Trials Begin for New Cancer Treatment by IRIC and Ipsen #Canada #cancer_therapy #Montreal #Ipsen #IRIC

Niche Guys - How Ipsen Solves Unique Thermal Processing Challenges - Ipsen Global Explore how Ipsen’s custom vacuum furnaces solve niche heat-treating challenges in additive manufacturing, aerospace, and more.

From AvaC low-pressure carburizing to Ion Vapor Deposition and Debinding-Sintering, Ipsen delivers solutions for even the most specialized thermal processing challenges. Learn more in the latest Ipsen Knowledge Center feature:
ipsenglobal.com/knowledge-ce...
#heat-treating #Ipsen #aerospace

Ipsen’s Iqirvo accepted by SMC to treat rare liver disease primary biliary cholangitis - PMLiVE The life-long condition affects approximately 1,900 people in Scotland

#hepatology #gastroenterology #Ipsen #Iqirvo #elafibranor #SMC #ScottishMedicinesConsortium #SMCapprovel #liverdisease #primarybiliarycholangitis #Scotland #NHSScotland #rarecholestaticliverdisease #NICE #NICErecommended #PBCpatients #ELATIVEtrial #cholestasis
pmlive.com/ipsens-iqirv...

Je me forme aux premiers secours | Croix-Rouge française Formez-vous aux premiers secours. N'hésitez plus, trouvez une session de formation près de chez vous et inscrivez-vous !

#IPSEN #GQS #PSC
C'est quoi ces trucs ?
On vous explique TOUT !
www.croix-rouge.fr/formations

Marengo Therapeutics Advances Second Drug Candidate Through Partnership with Ipsen Marengo Therapeutics announces the nomination of a second drug candidate from its collaboration with Ipsen, advancing innovative cancer therapies.

Marengo Therapeutics Advances Second Drug Candidate Through Partnership with Ipsen #United_States #Cambridge #biotechnology #Marengo_Therapeutics #Ipsen

Orphan Drugs: Für eine bessere Versorgung der Patient:innen Das Biopharmaunternehmen IPSEN hat konkrete Handlungsempfehlungen erarbeitet, um die Versorgung von Menschen mit seltenen Erkrankungen zu optimieren.

Das #Biopharmaunternehmen #IPSEN hat konkrete Handlungsempfehlungen erarbeitet, um die Versorgung von Menschen mit seltenen Erkrankungen zu optimieren: pharma-fakten.de/news/orphan-... #orphandrugs #Gesundheitspolitik #Gesundheitsversorgung

Ipsen enlists MAITs to take down solid tumors, betting $610M on Biomunex's novel T-cell engagers Ipsen has

#ipsen #cancer #tce

🌟 Merci à la société Ipsen pour leur engagement ! nous avons eu plaisir d'accueillir à Dreux des collaborateurs d’Ipsen pour une journée solidaire...
#jaimelesbouchons #Solidarite #Benevolat #Recyclage #bouchons #soutien #aide #Handicap #Ensemble
#Ipsen #RSE #journee #partage #Coeur2Bouchons

$IPN #ipsen

MMD 9 and 20 🆙
Prices approaching mm50⬇️

#Bourse #Dax40 #CAC40 #AEX #daytrading #stockstobuy #Nasdaq #Markets #BREAKOUTSTOCKS #BullFlag #Ibis